Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4998566 | 0.97 | SMN1; SMN2 (0.33) | SMN1; SMN2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3092593 | 0.75 | — | — | |
| SCHEMBL428337 | 0.75 | ESR2 (0.38) | SMN1; SMN2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL428515 | 0.71 | — | — | |
| SCHEMBL1177140 | 0.70 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL19255977 | 0.70 | CRBN (0.41) | SMN1; SMN2 | |
| SCHEMBL346851 | 0.70 | CRBN (0.41) | SMN1; SMN2 | |
| SCHEMBL11626081 | 0.68 | TSHR (0.36) | SMN1; SMN2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL395804 | 0.68 | TSHR (0.36) | SMN1; SMN2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL7338345 | 0.68 | TSHR (0.36) | SMN1; SMN2PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227792-A1 | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters | NOVO NORDISK A/S (DK) | 2008-09-18 | — | — | US | claimed |
| US-20080227792-A1 | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters | NOVO NORDISK A/S (DK) | 2008-09-18 | — | — | US | disclosed |
| EP-1853585-A1 | 3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID 5-AMINOPYRIDIN-2-YL ESTERS | Novo Nordisk A/S (DK) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006087309-A1 | 3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID 5-AMINOPYRIDIN-2-YL ESTERS | NOVO NORDISK A/S (DK) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227792-A1 | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters | LIPE, LIPC, PNLIP | SMN1; SMN2 2519/4885PIK3CD 1887/4885PIK3CA 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.